In human FLS from patients with RA, the potent AHR antagonist, GNF351, attenuated IL-1β–induced growth factor expression, IL-1β–induced proliferation, protease-dependent invasion, and migration in RA-FLS in an AHR-dependent manner (119). Here, IL1B is linked to rheumatoid arthritis.